癌症免疫治疗生物标志物学会工作组建议审查。

The Society for Immunotherapy of Cancer Biomarkers Task Force recommendations review.

机构信息

Departments of Medicine, Surgery, Immunology and Clinical and Translational Science, University of Pittsburgh, Pittsburgh, PA 15213, United States.

出版信息

Semin Cancer Biol. 2018 Oct;52(Pt 2):12-15. doi: 10.1016/j.semcancer.2017.09.006. Epub 2017 Sep 22.

DOI:10.1016/j.semcancer.2017.09.006

PMID:28943324

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5862764/

Abstract

The clinical successes in cancer immunotherapy have led to a critical need for biomarkers in cancer immunotherapy. It is of the utmost importance to know who is most likely to benefit from these therapies (predictive biomarkers) but also who is starting to respond (prognostic biomarkers) and how the therapy functions in order to make rational combination choices (mechanism of action biomarkers). The Society for Immunotherapy of Cancer (SITC) Biomarkers Task Force addressed the state of the art and made a series of recommendations for the field, which is summarized here.

摘要

癌症免疫疗法的临床成功导致了对癌症免疫疗法生物标志物的迫切需求。了解谁最有可能从这些治疗中受益（预测性生物标志物），谁开始有反应（预后性生物标志物），以及该疗法如何发挥作用以做出合理的联合选择（作用机制生物标志物）是至关重要的。癌症免疫治疗学会（SITC）生物标志物工作组探讨了该领域的最新技术，并提出了一系列建议，现总结如下。